XORTX Therapeutics Inc. (XRTX)
Automate Your Wheel Strategy on XRTX
With Tiblio's Option Bot, you can configure your own wheel strategy including XRTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol XRTX
- Rev/Share 0.0
- Book/Share 0.536
- PB 1.3197
- Debt/Equity 0.0396
- CurrentRatio 1.7774
- ROIC -1.7411
- MktCap 2679808.0
- FreeCF/Share -0.8192
- PFCF -0.8635
- PE -1.4222
- Debt/Assets 0.0293
- DivYield 0
- ROE -0.7361
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
XORTX Announces Pricing of US$1.1 Million Registered Direct Offering
Published: October 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
CALGARY, Alberta, Oct. 21, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that it has entered into a securities purchase agreement with an institutional investor for the purchase and sale of 1,746,631 common shares (or common share equivalents in lieu thereof) in a registered direct offering (the “Offering”) at a purchase price of US$0.63 per common share.
Read More
XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency
Published: October 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
CALGARY, Alberta, Oct. 20, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that a press release that had previously been issued on April 17, 2025 was re-issued in error today. Please disregard this prior press release.
Read More
XORTX Completes USD $114,500 Private Placement
Published: August 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Aug. 08, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces the closing of its previously announced non-brokered private placement of units (“Units”), whereby it issued 156,849 Units at a price of US$0.73 per Unit for aggregate gross proceeds of US$114,500 (the “Offering”). Under the Offering, each Unit consisted of one common share in the …
Read More
XORTX Announces USD $3 Million Offering
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
CALGARY, Alberta, May 19, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and gout, announces a non-brokered private placement to raise up to USD $3,000,000 through the issuance of up to 3,409,090 common share units of the Company at a price of USD $0.88 per unit (the “Offering”). Each Unit will comprise one common share and one common share purchase warrant (a “Warrant”).
Read More
About XORTX Therapeutics Inc. (XRTX)
- IPO Date 2021-09-23
- Website https://www.xortx.com
- Industry Biotechnology
- CEO Allen Warren Davidoff
- Employees 2